{"id":745382,"date":"2016-05-18T16:19:00","date_gmt":"2016-05-18T16:19:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-from-keynote-006-and-keynote-001-in-advanced-melanoma-including-updated-survival-data-to-be-presented-at-2016-asco-annual-meeting\/"},"modified":"2025-11-07T01:25:51","modified_gmt":"2025-11-07T06:25:51","slug":"new-keytruda-pembrolizumab-data-from-keynote-006-and-keynote-001-in-advanced-melanoma-including-updated-survival-data-to-be-presented-at-2016-asco-annual-meeting","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-from-keynote-006-and-keynote-001-in-advanced-melanoma-including-updated-survival-data-to-be-presented-at-2016-asco-annual-meeting\/","title":{"rendered":"New KEYTRUDA\u00ae (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting"},"content":{"rendered":"<p class=\"bwalignc\">       Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO;        KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate&nbsp;Overall        Survival Compared to Ipilimumab, Shows Continued Benefit with Longer        Follow-Up     <\/p>\n<p class=\"bwalignc\">       KEYNOTE-001 Findings Show Continued Benefit in Response Rates,        Duration of Response, and Include New Three-Year Overall Survival Data        for KEYTRUDA     <\/p>\n<\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced final overall survival (OS) data from KEYNOTE-006 and<br \/>\n      new findings from KEYNOTE-001, including updated response rates,<br \/>\n      duration of response data and three-year OS data with KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with<br \/>\n      unresectable or metastatic melanoma. Findings from the final OS analysis<br \/>\n      from KEYNOTE-006, a phase 3 study evaluating KEYTRUDA as monotherapy<br \/>\n      compared to ipilimumab, continue to show a significant survival benefit<br \/>\n      compared to ipilimumab in the first-line setting for advanced melanoma.<br \/>\n      These data will be presented at the 52<sup>nd<\/sup> Annual Meeting of<br \/>\n      the American Society of Clinical Oncology (ASCO) in Chicago, June 3 \u2013 7,<br \/>\n      2016.\n    <\/p>\n<p>\n      Long-term OS data from KEYNOTE-006 to be presented at ASCO showed that<br \/>\n      with KEYTRUDA, 55.1 percent and 55.3 percent of patients were alive two<br \/>\n      years after starting treatment (10 mg\/kg every two weeks and three<br \/>\n      weeks, respectively), compared to 43 percent of patients receiving<br \/>\n      ipilimumab (hazard ratio: 0.68 [95% CI, 0.53-0.87; p=0.0008] and hazard<br \/>\n      ratio: 0.68 [95% CI, 0.53-0.86; p=0.0008], respectively). These data<br \/>\n      will be presented by Dr. Jacob Schachter, Ella Institute for Research<br \/>\n      and Treatment of Melanoma, Sheba Medical Center, in an oral session on<br \/>\n      Monday, June 6, from 2:27 to 2:39 p.m. CDT (Location: Arie Crown<br \/>\n      Theater) (Abstract #9504).\n    <\/p>\n<p>\n      Additionally, data from KEYNOTE-001, including the long-term, three-year<br \/>\n      OS analysis, were featured in the official ASCO Press Program today and<br \/>\n      will be presented at ASCO in Chicago. The primary efficacy measure in<br \/>\n      KEYNOTE-001 was overall response rate (ORR), and secondary outcome<br \/>\n      measures included duration of response, progression-free survival (PFS)<br \/>\n      and OS. The data from KEYNOTE-001 discussed today will be presented<br \/>\n      along with additional findings in an oral session by Dr. Caroline<br \/>\n      Robert, Institut Gustave-Roussy, on Monday, June 6, from 2:15 to 2:27<br \/>\n      p.m. CDT (Location: Arie Crown Theater) (Abstract #9503).\n    <\/p>\n<p>\n      \u201cWith longer-term follow-up from two studies, including a head-to-head<br \/>\n      trial demonstrating superior survival compared to another immunotherapy,<br \/>\n      we are continuing to see durability of response with KEYTRUDA as<br \/>\n      monotherapy,\u201d said Dr. Roger Dansey, senior vice president and<br \/>\n      therapeutic area head, oncology late-stage development, Merck Research<br \/>\n      Laboratories. \u201cThese results add to the growing body of data supporting<br \/>\n      the use of KEYTRUDA as first-line treatment in advanced melanoma, and<br \/>\n      serve as an important reminder for what we are aiming to achieve through<br \/>\n      our immuno-oncology development program \u2013 enhanced survival for people<br \/>\n      with cancer.\u201d\n    <\/p>\n<p>\n      Findings from the melanoma cohorts of the phase 1b KEYNOTE-001 trial,<br \/>\n      which included 655 patients, showed an ORR of 33 percent (per RECIST<br \/>\n      v1.1). At the time of the analysis, a response duration of two years or<br \/>\n      more was observed in 73 percent of patients. Long-term OS data showed an<br \/>\n      estimated 40 percent of patients were alive three years after starting<br \/>\n      treatment with\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab), with a median survival of 24.4 months (95% CI,<br \/>\n      20.2-29.0). Median duration of response has not yet been reached (range,<br \/>\n      1.3+ to 38.8+).\n    <\/p>\n<p>\n      Data from KEYNOTE-001 served as the basis for the U.S. Food and Drug<br \/>\n      Administration\u2019s accelerated approval of KEYTRUDA in September 2014. The<br \/>\n      label was subsequently updated to reflect data from the KEYNOTE-006<br \/>\n      (phase 3) and KEYNOTE-002 (phase 2) trials, expanding the indication to<br \/>\n      include treatment of first-line advanced melanoma regardless of BRAF<br \/>\n      status. Today, KEYTRUDA is approved for the treatment of advanced<br \/>\n      melanoma in more than 50 countries, including the United States and<br \/>\n      throughout Europe.\n    <\/p>\n<p>\n      The KEYTRUDA clinical development program includes more than 30 tumor<br \/>\n      types in more than 270 clinical trials, including more than 100 trials<br \/>\n      that combine KEYTRUDA with other cancer treatments.\n    <\/p>\n<p>\n      <b>Key Findings from the KEYNOTE-006 Study<\/b>\n    <\/p>\n<p>\n      KEYNOTE-006 is a global, open-label, randomized, pivotal, phase 3 study<br \/>\n      evaluating KEYTRUDA (pembrolizumab) compared to ipilimumab in patients<br \/>\n      with unresectable stage III or IV advanced melanoma with no more than<br \/>\n      one prior systemic therapy. The study randomized 834 patients to receive<br \/>\n      KEYTRUDA 10 mg\/kg every three weeks, KEYTRUDA 10 mg\/kg every two weeks,<br \/>\n      or four cycles of ipilimumab 3 mg\/kg every three weeks. The co-primary<br \/>\n      endpoints were PFS and OS; secondary endpoints were ORR, duration of<br \/>\n      response and safety, with an exploratory analysis for health-related<br \/>\n      quality of life (QoL). Tumor response was assessed at week 12, then<br \/>\n      every 6 weeks thereafter per RECIST v1.1 by independent, central,<br \/>\n      blinded radiographic review and investigator-assessed, immune-related<br \/>\n      response criteria.\n    <\/p>\n<p>\n      Based on data to be presented at ASCO, KEYTRUDA (10 mg\/kg every two or<br \/>\n      three weeks) continued to provide superior OS, PFS and ORR compared to<br \/>\n      ipilimumab. Specifically, long-term OS data showed 55.1 percent and 55.3<br \/>\n      percent of patients were alive two years after starting treatment with<br \/>\n      KEYTRUDA (every two weeks and three weeks, respectively) compared to 43<br \/>\n      percent of patients receiving ipilimumab (hazard ratio: 0.68 [95% CI,<br \/>\n      0.53-0.87; p=0.0008] and hazard ratio: 0.68 [95% CI, 0.53-0.86;<br \/>\n      p=0.0008], respectively). Median OS was not reached for KEYTRUDA; for<br \/>\n      ipilimumab, median OS was 16 months.\n    <\/p>\n<p>\n      Additionally, an estimated 31.2 percent and 27.8 percent of patients<br \/>\n      receiving KEYTRUDA (every two weeks and three weeks, respectively) were<br \/>\n      alive and were disease progression-free at two years compared to 13.5<br \/>\n      percent of patients receiving ipilimumab (hazard ratio: 0.61 [95% CI,<br \/>\n      0.50-0.75; p&lt;0.0001] for both). For patients receiving KEYTRUDA, ORR was<br \/>\n      36.9 percent and 36.1 percent (every two weeks and three weeks,<br \/>\n      respectively) compared to 13.3 percent for patients receiving ipilimumab<br \/>\n      (p&lt;0.0001 for both groups).\n    <\/p>\n<p>\n      With longer follow-up, adverse events have remained consistent with<br \/>\n      previously reported safety data. There was one treatment-related death<br \/>\n      (due to sepsis) in the KEYTRUDA every two week group.\n    <\/p>\n<p>\n      <b>Key Findings from the KEYNOTE-001 Study<\/b>\n    <\/p>\n<p>\n      KEYNOTE-001 is a phase 1b multicenter, open-label, multi-cohort trial<br \/>\n      evaluating KEYTRUDA in various advanced cancers, including advanced<br \/>\n      melanoma. Patients in the melanoma cohorts received 2 mg\/kg or 10 mg\/kg<br \/>\n      of KEYTRUDA every three weeks or 10 mg\/kg of KEYTRUDA every two weeks<br \/>\n      until unacceptable toxicity or disease progression. The major efficacy<br \/>\n      outcome measure was confirmed ORR as assessed by blinded independent<br \/>\n      central review using RECIST v1.1. Tumor response was assessed every 12<br \/>\n      weeks. The secondary outcome measures included PFS, OS and duration of<br \/>\n      response.\n    <\/p>\n<p>\n      The findings to be presented at ASCO include updated response rates and<br \/>\n      duration of response data, as well as three-year OS data from the 655<br \/>\n      patients with unresectable or metastatic melanoma and progression of<br \/>\n      disease. All patients were followed for at least two years, with some<br \/>\n      being followed for almost four years (with median follow-up duration of<br \/>\n      32 months).\n    <\/p>\n<p>\n      Of those patients who responded to treatment with KEYTRUDA<br \/>\n      (pembrolizumab), a complete response (CR) was observed in 10 percent of<br \/>\n      patients. Among the 61 patients who stopped treatment once a complete<br \/>\n      response had occurred, the response duration ranged from 17+ to 44+<br \/>\n      months (median duration not reached). Only two patients who had a<br \/>\n      complete response experienced disease progression after stopping<br \/>\n      treatment. In addition, long-term survival data showed that 40 percent<br \/>\n      of patients survived three years after starting treatment with KEYTRUDA<br \/>\n      (n=655).\n    <\/p>\n<p>\n      With longer follow-up, adverse events have remained consistent with<br \/>\n      previously reported safety data. Immune-mediated treatment-related<br \/>\n      adverse events observed in this trial were hypothyroidism (9.6%),<br \/>\n      pneumonitis (4.3%), hyperthyroidism (2.3%), colitis (2.3%), uveitis<br \/>\n      (1.5%), hepatitis (0.9%), and nephritis (0.5%).\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b> (pembrolizumab) Injection<br \/>\n      100 mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with metastatic<br \/>\n      non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as<br \/>\n      determined by an FDA-approved test with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. An improvement in survival or<br \/>\n      disease-related symptoms has not yet been established. Continued<br \/>\n      approval for this indication may be contingent upon verification and<br \/>\n      description of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      KEYTRUDA is administered at a dose of 2 mg\/kg as an intravenous infusion<br \/>\n      over 30 minutes every three weeks for the approved indications.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      Immune-mediated pneumonitis, including fatal cases, occurred in patients<br \/>\n      receiving KEYTRUDA. Pneumonitis occurred in 32 (2.0%) of 1567 patients,<br \/>\n      including Grade 1 (0.8%), 2 (0.8%), and 3 (0.4%) pneumonitis. Monitor<br \/>\n      patients for signs and symptoms of pneumonitis. Evaluate suspected<br \/>\n      pneumonitis with radiographic imaging. Administer corticosteroids for<br \/>\n      Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2;<br \/>\n      permanently discontinue KEYTRUDA for Grade 3 or 4 or recurrent Grade 2<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Immune-mediated colitis occurred in 31 (2%) of 1567 patients, including<br \/>\n      Grade 2 (0.5%), 3 (1.1%), and 4 (0.1%) colitis. Monitor patients for<br \/>\n      signs and symptoms of colitis. Administer corticosteroids for Grade 2 or<br \/>\n      greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Immune-mediated hepatitis occurred in 16 (1%) of 1567 patients,<br \/>\n      including Grade 2 (0.1%), 3 (0.7%), and 4 (0.1%) hepatitis. Monitor<br \/>\n      patients for changes in liver function. Administer corticosteroids for<br \/>\n      Grade 2 or greater hepatitis and, based on severity of liver enzyme<br \/>\n      elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 13 (0.8%) of 1567 patients, including Grade 2<br \/>\n      (0.3%), 3 (0.3%), and 4 (0.1%) hypophysitis. Monitor patients for signs<br \/>\n      and symptoms of hypophysitis (including hypopituitarism and adrenal<br \/>\n      insufficiency). Administer corticosteroids and hormone replacement as<br \/>\n      clinically indicated. Withhold KEYTRUDA for Grade 2; withhold or<br \/>\n      discontinue for Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 51 (3.3%) of 1567 patients, including Grade<br \/>\n      2 (0.6%) and 3 (0.1%) hyperthyroidism. Hypothyroidism occurred in 127<br \/>\n      (8.1%) of 1567 patients, including Grade 3 (0.1%) hypothyroidism.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 3<br \/>\n      (0.1%) of 2117 patients. Monitor patients for hyperglycemia or other<br \/>\n      signs and symptoms of diabetes. Administer insulin for type 1 diabetes,<br \/>\n      and withhold KEYTRUDA and administer anti-hyperglycemics in patients<br \/>\n      with severe hyperglycemia.\n    <\/p>\n<p>\n      Immune-mediated nephritis occurred in 7 (0.4%) of 1567 patients,<br \/>\n      including Grade 2 (0.2%), 3 (0.2%), and 4 (0.1%) nephritis. Monitor<br \/>\n      patients for changes in renal function. Administer corticosteroids for<br \/>\n      Grade 2 or greater nephritis. Withhold KEYTRUDA for Grade 2; permanently<br \/>\n      discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA (pembrolizumab) and<br \/>\n      administer corticosteroids. Upon improvement to Grade 1 or less,<br \/>\n      initiate corticosteroid taper and continue to taper over at least 1<br \/>\n      month. Based on limited data from clinical studies in patients whose<br \/>\n      immune-related adverse reactions could not be controlled with<br \/>\n      corticosteroid use, administration of other systemic immunosuppressants<br \/>\n      can be considered. Resume KEYTRUDA when the adverse reaction remains at<br \/>\n      Grade 1 or less following corticosteroid taper. Permanently discontinue<br \/>\n      KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs<br \/>\n      and for any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 1567 patients:<br \/>\n      arthritis (1.6%), exfoliative dermatitis, bullous pemphigoid, uveitis,<br \/>\n      myositis, Guillain-Barr\u00e9 syndrome, myasthenia gravis, vasculitis,<br \/>\n      pancreatitis, hemolytic anemia, and partial seizures arising in a<br \/>\n      patient with inflammatory foci in brain parenchyma.\n    <\/p>\n<p>\n      Severe and life-threatening infusion-related reactions have been<br \/>\n      reported in 3 (0.1%) of 2117 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In Trial 6, KEYTRUDA was discontinued due to adverse reactions in 9% of<br \/>\n      555 patients; adverse reactions leading to discontinuation in more than<br \/>\n      one patient were colitis (1.4%), autoimmune hepatitis (0.7%), allergic<br \/>\n      reaction (0.4%), polyneuropathy (0.4%), and cardiac failure (0.4%).<br \/>\n      Adverse reactions leading to interruption of KEYTRUDA occurred in 21% of<br \/>\n      patients; the most common (\u22651%) was diarrhea (2.5%). The most common<br \/>\n      adverse reactions with KEYTRUDA vs ipilimumab were fatigue (28% vs 28%),<br \/>\n      diarrhea (26% with KEYTRUDA), rash (24% vs 23%), and nausea (21% with<br \/>\n      KEYTRUDA). Corresponding incidence rates are listed for ipilimumab only<br \/>\n      for those adverse reactions that occurred at the same or lower rate than<br \/>\n      with KEYTRUDA.\n    <\/p>\n<p>\n      In Trial 2, KEYTRUDA was discontinued due to adverse reactions in 12% of<br \/>\n      357 patients; the most common (\u22651%) were general physical health<br \/>\n      deterioration (1%), asthenia (1%), dyspnea (1%), pneumonitis (1%), and<br \/>\n      generalized edema (1%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA (pembrolizumab) occurred in 14% of patients; the most common<br \/>\n      (\u22651%) were dyspnea (1%), diarrhea (1%), and maculo-papular rash (1%).<br \/>\n      The most common adverse reactions with KEYTRUDA (pembrolizumab) vs<br \/>\n      chemotherapy were fatigue (43% with KEYTRUDA), pruritus (28% vs 8%),<br \/>\n      rash (24% vs 8%), constipation (22% vs 20%), nausea (22% with KEYTRUDA),<br \/>\n      diarrhea (20% vs 20%), and decreased appetite (20% with KEYTRUDA).<br \/>\n      Corresponding incidence rates are listed for chemotherapy only for those<br \/>\n      adverse reactions that occurred at the same or lower rate than with<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      No formal pharmacokinetic drug interaction studies have been conducted<br \/>\n      with KEYTRUDA.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 270 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51345590&amp;newsitemid=20160518006541&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=352d5a5ef63d768ed74ef3120e7ab3e6\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51345590&amp;newsitemid=20160518006541&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=acff000164c6c09e89a66ef7eab02975\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51345590&amp;newsitemid=20160518006541&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=839c5202dcf93c8564037ae725a3e3db\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51345590&amp;newsitemid=20160518006541&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=dc0c37d5a5231ac977d4780238648531\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51345590&amp;newsitemid=20160518006541&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=a0778b0ec888703482d58a3bf11ff1e3\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51345590&amp;newsitemid=20160518006541&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=4909d8fd0e562a84a87740da01540b42\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51345590&amp;newsitemid=20160518006541&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=f9f12647eac96af9e1a5393bfc3f21af\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51345590&amp;newsitemid=20160518006541&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=11854d9bc2b078b33224e49fbd93da51\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><\/a><b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51345590&amp;newsitemid=20160518006541&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=1ff046fd874c812ea845d8a9391f30e5\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160518006541r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>An Phan,        908-255-6325<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Justin        Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate&nbsp;Overall Survival Compared to Ipilimumab, Shows Continued Benefit with Longer Follow-Up KEYNOTE-001 Findings Show Continued Benefit in Response Rates, Duration of Response, and Include New Three-Year Overall Survival Data for KEYTRUDA Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced final overall survival (OS) data from KEYNOTE-006 and new findings from KEYNOTE-001, including updated response rates, duration of response data and three-year OS data with KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with unresectable or metastatic melanoma. Findings from the final OS analysis from KEYNOTE-006, a phase 3 study evaluating KEYTRUDA as monotherapy compared to ipilimumab, continue to show a significant survival benefit compared to ipilimumab in the first-line setting for advanced melanoma. These data<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745382","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New KEYTRUDA\u00ae (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-from-keynote-006-and-keynote-001-in-advanced-melanoma-including-updated-survival-data-to-be-presented-at-2016-asco-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New KEYTRUDA\u00ae (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate&nbsp;Overall Survival Compared to Ipilimumab, Shows Continued Benefit with Longer Follow-Up KEYNOTE-001 Findings Show Continued Benefit in Response Rates, Duration of Response, and Include New Three-Year Overall Survival Data for KEYTRUDA Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced final overall survival (OS) data from KEYNOTE-006 and new findings from KEYNOTE-001, including updated response rates, duration of response data and three-year OS data with KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with unresectable or metastatic melanoma. Findings from the final OS analysis from KEYNOTE-006, a phase 3 study evaluating KEYTRUDA as monotherapy compared to ipilimumab, continue to show a significant survival benefit compared to ipilimumab in the first-line setting for advanced melanoma. These data\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-from-keynote-006-and-keynote-001-in-advanced-melanoma-including-updated-survival-data-to-be-presented-at-2016-asco-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-keytruda-pembrolizumab-data-from-keynote-006-and-keynote-001-in-advanced-melanoma-including-updated-survival-data-to-be-presented-at-2016-asco-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-keytruda-pembrolizumab-data-from-keynote-006-and-keynote-001-in-advanced-melanoma-including-updated-survival-data-to-be-presented-at-2016-asco-annual-meeting\\\/\",\"name\":\"New KEYTRUDA\u00ae (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-05-18T16:19:00+00:00\",\"dateModified\":\"2025-11-07T06:25:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-keytruda-pembrolizumab-data-from-keynote-006-and-keynote-001-in-advanced-melanoma-including-updated-survival-data-to-be-presented-at-2016-asco-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-keytruda-pembrolizumab-data-from-keynote-006-and-keynote-001-in-advanced-melanoma-including-updated-survival-data-to-be-presented-at-2016-asco-annual-meeting\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-keytruda-pembrolizumab-data-from-keynote-006-and-keynote-001-in-advanced-melanoma-including-updated-survival-data-to-be-presented-at-2016-asco-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New KEYTRUDA\u00ae (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New KEYTRUDA\u00ae (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-from-keynote-006-and-keynote-001-in-advanced-melanoma-including-updated-survival-data-to-be-presented-at-2016-asco-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"New KEYTRUDA\u00ae (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting - Merck.com","og_description":"Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate&nbsp;Overall Survival Compared to Ipilimumab, Shows Continued Benefit with Longer Follow-Up KEYNOTE-001 Findings Show Continued Benefit in Response Rates, Duration of Response, and Include New Three-Year Overall Survival Data for KEYTRUDA Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced final overall survival (OS) data from KEYNOTE-006 and new findings from KEYNOTE-001, including updated response rates, duration of response data and three-year OS data with KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with unresectable or metastatic melanoma. Findings from the final OS analysis from KEYNOTE-006, a phase 3 study evaluating KEYTRUDA as monotherapy compared to ipilimumab, continue to show a significant survival benefit compared to ipilimumab in the first-line setting for advanced melanoma. These data","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-from-keynote-006-and-keynote-001-in-advanced-melanoma-including-updated-survival-data-to-be-presented-at-2016-asco-annual-meeting\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:51+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-from-keynote-006-and-keynote-001-in-advanced-melanoma-including-updated-survival-data-to-be-presented-at-2016-asco-annual-meeting\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-from-keynote-006-and-keynote-001-in-advanced-melanoma-including-updated-survival-data-to-be-presented-at-2016-asco-annual-meeting\/","name":"New KEYTRUDA\u00ae (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-05-18T16:19:00+00:00","dateModified":"2025-11-07T06:25:51+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-from-keynote-006-and-keynote-001-in-advanced-melanoma-including-updated-survival-data-to-be-presented-at-2016-asco-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-from-keynote-006-and-keynote-001-in-advanced-melanoma-including-updated-survival-data-to-be-presented-at-2016-asco-annual-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-from-keynote-006-and-keynote-001-in-advanced-melanoma-including-updated-survival-data-to-be-presented-at-2016-asco-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"New KEYTRUDA\u00ae (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"efb84355-6a67-4466-b5c1-89ca6a98e058","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/New-KEYTRUDA-pembrolizumab-Data-from-KEYNOTE-006-and-KEYNOTE-001-in-Advanced-Melanoma-Including-Updated-Survival-Data-To-Be-Presented-ICC1K.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745382","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745382\/revisions"}],"predecessor-version":[{"id":3674778,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745382\/revisions\/3674778"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745382"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}